Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): -N(R9)-C(-X)-(Y)n-R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.